[Consensus document on the clinical use of melatonin in children and adolescents with sleep-onset insomnia].

Autor:	Pin Arboledas G; Asociación Española de Pediatría (AEP), Valencia, España. Electronic address: pinarboledasgonzalo@gmail.com., Merino Andreu M; Sociedad Española de Sueño (SES), Madrid, España., de la Calle Cabrera T; Sociedad Española de Pediatría Extrahospitalaria y Atención Primaria (SEPEAP), Salamanca, España., Hidalgo Vicario MI; Sociedad Española de Medicina de la Adolescencia (SEMA), Madrid, España., Rodríguez Hernández PJ; Sociedad de Psiquiatría Infantil (SPI), Tenerife, España., Soto Insuga V; Sociedad Española de Neurología Pediátrica (SENEP), Madrid, España., Madrid Pérez JA; Laboratorio de Cronobiología, Departamento de Fisiología, Universidad de Murcia, Murcia, España.
Jazyk:	Spanish; Castilian
Zdroj:	Anales de pediatria (Barcelona, Spain : 2003) [An Pediatr (Barc)] 2014 Nov; Vol. 81 (5), pp. 328.e1-9. Date of Electronic Publication: 2014 Apr 24.
DOI:	10.1016/j.anpedi.2014.03.011
Abstrakt:	Sleep problems are highly prevalent among our children and adolescents. Its treatment is mainly based on cognitive behavioural therapies and habit modification procedures. However, the use of sleep promoting drugs and substances is widespread without being supported by clinical guidelines. Exogenous melatonin is a neurohormone marketed as a nutritional supplement that is being increasingly used in the management of sleep problems, and with no control over its use. The consensus document is presented on the use of melatonin in sleep-onset insomnia prepared by representatives of the Spanish Paediatric Association, the Spanish Society of Sleep, the Spanish Society of Paediatric Outpatients and Primary Care, the Spanish Society for Adolescent Medicine, the Spanish Society of Child Psychiatry, and the Spanish Society of Paediatric Neurology. (Copyright © 2014 Asociación Española de Pediatría. Published by Elsevier Espana. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu